[HTML][HTML] FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
…, VL Mulcahy, RE Kuc, TL Williams… - Nature, 2023 - nature.com
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting
enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for …
enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for …
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
…, J McLauchlan, DJ Mutimer, A Brown, WTH Gelson… - Journal of …, 2016 - Elsevier
Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
…, J McLauchlan, DJ Mutimer, A Brown, WTH Gelson… - Journal of …, 2016 - Elsevier
Background & Aims Direct-acting antivirals have become widely used for patients with
chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are …
chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are …
Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation
…, E Melum, TH Karlsen, JA Bradley, WTH Gelson… - Nature …, 2015 - nature.com
The study of biliary disease has been constrained by a lack of primary human cholangiocytes.
Here we present an efficient, serum-free protocol for directed differentiation of human …
Here we present an efficient, serum-free protocol for directed differentiation of human …
Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation
E Unitt, A Marshall, W Gelson, SM Rushbrook… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: Liver transplantation is an effective treatment for highly selected
patients with hepatocellular carcinoma (HCC), but tumour recurrence remains an important …
patients with hepatocellular carcinoma (HCC), but tumour recurrence remains an important …
Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids
…, SE Davies, KB Jensen, M Zilbauer, WTH Gelson… - Nature medicine, 2017 - nature.com
The treatment of common bile duct (CBD) disorders, such as biliary atresia or ischemic
strictures, is restricted by the lack of biliary tissue from healthy donors suitable for surgical …
strictures, is restricted by the lack of biliary tissue from healthy donors suitable for surgical …
Cholangiocyte organoids can repair bile ducts after transplantation in the human liver
Organoid technology holds great promise for regenerative medicine but has not yet been
applied to humans. We address this challenge using cholangiocyte organoids in the context of …
applied to humans. We address this challenge using cholangiocyte organoids in the context of …
The pattern of late mortality in liver transplant recipients in the United Kingdom
W Gelson, M Hoare, MF Dawwas, S Vowler… - …, 2011 - journals.lww.com
Background. Late survival is not improving after liver transplantation. In this study, possible
reasons for this were investigated. Methods. Mortality rates and causes of death were …
reasons for this were investigated. Methods. Mortality rates and causes of death were …
[PDF][PDF] Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system
…, GF Mells, B Srivastava, K Spiess, WTH Gelson… - …, 2019 - Wiley Online Library
We sought to identify factors that are predictive of liver transplantation or death in patients
with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous …
with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous …
[HTML][HTML] CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection
M Hoare, WTH Gelson, A Das, JM Fletcher… - Journal of …, 2010 - Elsevier
BACKGROUND & AIMS: Increasing age is associated with impaired immune function and in
chronic HCV infection specifically, with progressive fibrosis, liver failure, HCC and impaired …
chronic HCV infection specifically, with progressive fibrosis, liver failure, HCC and impaired …